These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 24856612

  • 1. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J, Fonseca V, Schinzel S, Dain MP, Mullins P, Riddle M.
    J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
    [Abstract] [Full Text] [Related]

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, Johnston P.
    Pediatr Diabetes; 2013 Dec 09; 14(8):593-601. PubMed ID: 23730996
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.
    Diabetes Obes Metab; 2015 Jan 09; 17(1):15-22. PubMed ID: 24957785
    [Abstract] [Full Text] [Related]

  • 7. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU.
    Clin Ther; 2007 Aug 09; 29(8):1607-19. PubMed ID: 17919543
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2011 Mar 09; 49(3):217-30. PubMed ID: 21329624
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E, Weatherley-Jones E, Chilcott J, Beverley C.
    Health Technol Assess; 2004 Nov 09; 8(45):iii, 1-57. PubMed ID: 15525480
    [Abstract] [Full Text] [Related]

  • 11. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group.
    Ann Intern Med; 2003 Jun 17; 138(12):952-9. PubMed ID: 12809451
    [Abstract] [Full Text] [Related]

  • 12. Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials.
    Polonsky W, Traylor L, Gao L, Wei W, Ameer B, Stuhr A, Vlajnic A.
    J Diabetes Complications; 2017 Mar 17; 31(3):562-568. PubMed ID: 28040350
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
    Dailey GE, Gao L, Aurand L, Garg SK.
    Diabetes Obes Metab; 2013 Dec 17; 15(12):1085-92. PubMed ID: 23683002
    [Abstract] [Full Text] [Related]

  • 19. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
    Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J, HOE 901/4013 LA Study Group.
    Arch Med Res; 2006 May 17; 37(4):495-501. PubMed ID: 16715577
    [Abstract] [Full Text] [Related]

  • 20. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
    Yeldandi RR, Lurie A, Baldwin D.
    Diabetes Technol Ther; 2006 Dec 17; 8(6):609-16. PubMed ID: 17109592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.